Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Shots:
- Lilly has expanded its ongoing BLAZE-4 trial to assess the administration of bamlanivimab (700mg) with VIR-7831 (500mg) for symptomatic COVID-19 in the outpatient setting. These are two neutralizing Abs that bind to different epitopes of the SARS-CoV-2 spike protein
- The companies reported the first patient has been dosed in the expanded study
- Bamlanivimab is authorized for emergency use in the US for mild-to-mod. COVID-19 in high-risk patients. VIR-7831 is being evaluated in the global P-II/III COMET-ICE trial for the early treatment of COVID-19 in adults at high risk of hospitalization
Ref: GSk | Image: GSk
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com